The Dilated Cardiomyopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dilated Cardiomyopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued products.

GlobalData tracks 38 drugs in development for Dilated Cardiomyopathy by 23 companies/universities/institutes. The top development phase for Dilated Cardiomyopathy is preclinical with 16 drugs in that stage. The Dilated Cardiomyopathy pipeline has 37 drugs in development by companies and one by universities/ institutes. Some of the companies in the Dilated Cardiomyopathy pipeline products market are: DiNAQOR, Solid Biosciences and Tenaya Therapeutics.

The key targets in the Dilated Cardiomyopathy pipeline products market include BAG Family Molecular Chaperone Regulator 3 (Bcl 2 Associated Athanogene 3 or Bcl 2 Binding Protein Bis or Docking Protein CAIR 1 or BAG3), High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), and Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98).

The key mechanisms of action in the Dilated Cardiomyopathy pipeline product include BAG Family Molecular Chaperone Regulator 3 (Bcl 2 Associated Athanogene 3 or Bcl 2 Binding Protein Bis or Docking Protein CAIR 1 or BAG3) Activator with two drugs in Preclinical. The Dilated Cardiomyopathy pipeline products include ten routes of administration with the top ROA being Intravenous and seven key molecule types in the Dilated Cardiomyopathy pipeline products market including Gene Therapy, and Cell Therapy.

Dilated Cardiomyopathy overview

Dilated cardiomyopathy (DCM) is a condition in which the heart’s ability to pump blood is decreased because the heart’s main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include fatigue and weakness, shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention, and swelling (edema) in legs, ankles, and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse, and metabolic disorders, such as thyroid disease or diabetes.

For a complete picture of Dilated Cardiomyopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.